Navigation Links
ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Date:12/11/2007

LEUVEN, Belgium, December 11 /PRNewswire-FirstCall/ --

- TB-402 Shows Clear Promise as a Stable Long-acting Anticoagulant for the Prevention of Thromboembolic Disorders.

ThromboGenics NV (Euronext Brussels:THR), a biotechnology company focused on vascular and eye disease, announced that the results of the first Phase I trial of TB-402 were presented yesterday at the prestigious American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Georgia, USA. TB-402 is being co-developed in collaboration with BioInvent International (Nordic Exchange: BINV).

TB-402 is a recombinant human monoclonal antibody which has shown a beneficial partial inhibition of the blood coagulation Factor VIII. Its long half life of approximately three weeks enables it to produce a stable and long-acting inhibition. This indicates well-controlled inhibition of Factor VIII activity with low risk of spontaneous bleeding, thus avoiding the possibility of overdose and the need for patient monitoring.

These unique features may be of major clinical significance, as it suggests that a product with an excellent safety profile, with ease of administration and compliance superior to alternative anticoagulants, can be developed. The preliminary results of the initial Phase I study were previously communicated in a Press Release issued September 7, 2007.

The Phase I trial presented at ASH was a randomized, single-dose, placebo-controlled, dose escalation trial in healthy male volunteers. 56 subjects were enrolled into the trial, including both younger age (18-45) and older age (55-76) volunteers. Results of the trial show that TB-402 is both safe and well-tolerated. No serious adverse events related to TB-402 were reported. In addition, there were no major bleeding complications, with the overall incidence being similar in both the TB-402 treated group and the patients who received placebo.

The pharmacokinetic analysis undertaken as part of the study
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 BerGenBio AS ("BerGenBio" or ... an abstract on the latest data on BGB324, the ... receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal ... in conjunction with the 2015 American Society of Clinical ... , May 29 - June 2, 2015. ...
(Date:5/29/2015)... 29, 2015 Market Publishers Ltd ... signed a partnership agreement for quality market research ... distribute and sell research reports worked out by ... Department, commented upon the agreement: “Chem-Report is a ... petroleum and chemical markets on global and country ...
(Date:5/29/2015)... Texas , May 29, 2015  Caris ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the clinical utility of Caris ... tumor profiling service, in helping to identify targeted ... tumors. In each of the studies, results of ...
(Date:5/29/2015)... Seoul Semiconductor (CEO: Chung-hoon Lee, http://www.seoulsemicon.com ... 28th announced that it will increase the global ... efficient and high reliable LED product line-up for ... has developed efficient and reliable LED packages for ... for headlamps to global auto makers. Seoul Semiconductor’s ...
Breaking Biology Technology:BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2
...  Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology ... results for the first quarter ended March 31, 2012 ... will host a conference call at 5:00 p.m. Eastern ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ) Those wishing to ...
... announced today the launch and immediate availability of the GS GType ... variation detection in four key human genes using the company,s ... sequence-based assays offer a new solution for cancer researchers investigating the ... RUNX1 genes, which are known to be associated with ...
... research team this week will present findings that they ... and breast cancer. "Cells have different ... chemical name for alcohol, that represent a potential risk ... pharmacology and toxicology at the Universidad Autonoma del Estado ...
Cached Biology Technology:Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide 2Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide 3Researchers Find Potential Link Between Drinking Alcohol And Breast Cancer 2Researchers Find Potential Link Between Drinking Alcohol And Breast Cancer 3
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... released today in the EarlyView of Ecology Letters ... shift in biomes caused by a warming climate. The ... Center and three other institutions based in Alaska and ... tree-ring data set. Patterns observed support current hypotheses regarding ...
... It,s a discordant note in the symphony of ... Stem cells hold enormous promise in regenerative medicine, thanks ... They have made it possible to markedly improve the ... cases of dystrophy, skin grafts for treating burn victims, ...
... breakthrough, a new blood pressure measurement device is set to ... new approach, invented by scientists at the University of Leicester ... treat their patients more effectively because it gives a more ... by measuring the pressure close to the heart the ...
Cached Biology News:New study illustrates shifting biomes in Alaska 2Reprogrammed stem cells hit a roadblock 2Groundbreaking technology will revolutionize blood pressure measurement 2Groundbreaking technology will revolutionize blood pressure measurement 3Groundbreaking technology will revolutionize blood pressure measurement 4
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
... GenBank Accession Number : ... (C-QSQENQDTRPKVKAKK), corresponding to amino acids ... Formulation: antiserum in 0.05% sodium ... Assurance: routinely evaluated by immunoblot ...
Request Info...
...
Biology Products: